Medicine
DaTscan 2 mCi/mL injection
DaTscan 2 mCi/mL injection is a prescription medicine containing Ioflupane i-123 for intravenous use, marketed by GE Healthcare, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store DATSCAN at 20° to 25°C (68° to 77°F). Store DATSCAN within the original…
Key facts
- Active ingredient (INN)
- Ioflupane i-123
- Brand
- DaTscan
- Strength
- 2 mCi/mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial
- Marketing authorisation holder
- GE Healthcare
- Manufacturer
- GE Healthcare
- Origin register
- US FDA, United States
- Storage
- Store DATSCAN at 20° to 25°C (68° to 77°F). Store DATSCAN within the original lead container or equivalent radiation shielding.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- V09AB03 Ioflupane i-123
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 March 2011
- Identifiers
- DailyMed set ID ef7804d7-c691-495b-8aaf-5bc54fd5d9f6NDC 17156-210Application NDA022454
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, glass in 1 container / 2.5 mL in 1 vial, glass | 17156-210-01 | GE Healthcare | 1 March 2011 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 14 January 2011 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Ioflupane i-123 2 mCi/mL injection.
Clinical summary
Ioflupane i-123 is a radioactive diagnostic agent. It is available as injection for intravenous use. MedsAcross supplies Ioflupane i-123 for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Ioflupane i-123For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- DaTscan prescribing information (GE Healthcare) · U.S. National Library of Medicine, DailyMed
Need DaTscan 2 mCi/mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.